Deafness-causing protein deficiency may cause brain to rewire itself
CORVALLIS, OREGON – The brains of people with congenital deafness may be rewiring themselves in ways that affect how those people learn, suggesting a need to develop new teaching techniques tailored toward those who have never been able to hear. Published earlier this month in Nature Scientific Reports, the findings by an Oregon State University…
Read More
Phonak Celebrates One Million Marvel Hearing Aids Fit
STAFA, SWITZERLAND – Phonak announced today that hearing care professionals around the world have fit one million Marvel hearing aids in only ten months. This makes Phonak Marvel the fastest product to reach the one million milestone in Phonak history and puts Marvel on track to be the company’s best-selling hearing aid of all time.…
Read More
FDA Grants FX-322 Fast Track Designation, for Treatment of Sensorineural Hearing Loss
WOBURN, MASSACHUSETTS — Biotech startup Frequency Therapeutics today announced that dosing has commenced in a Phase 2a clinical study of FX-322, a locally administered investigational drug candidate designed to regenerate auditory hair cells and restore hearing function. The objectives of the Phase 2a study are to further establish the positive hearing signal observed in Frequency’s…
Read More
Starkey Announces All-Star Lineup for Hearing Innovation Expo 2020
Starkey Hearing Technologies announced that it is hosting the fifth Hearing Innovation Expo at The Cosmopolitan of Las Vegas. This year’s event, which is being held on January 15-19, 2020, is expected to see more than 3,000 hearing professionals, scientists, industry experts and business leaders from more than 30 countries in attendance. Keynote speakers include Starkey…
Read More
New Research Finds Mild-to-Moderate Hearing Loss in Childhood Changes How Brain Processes Sound
CAMBRIDGE, UNITED KINGDOM — Deafness in early childhood is known to lead to lasting changes in how sounds are processed in the brain, but newly published research shows that even mild-to-moderate levels of hearing loss in young children can lead to similar changes. Researchers say that the findings may have implications for how babies are…
Read More
Frequency Therapeutics Goes Public; Company Debuts IPO at $84M
WOBURN, MASSACHUSSETTS — Biotech startup Frequency Therapeutics announced the pricing of its initial public offering (IPO) at approximately $84 million. The company is planning to use funds raised by the IPO to complete the Phase 2a trial of FX-322, a regenerative therapeutic for the treatment of sensorineural hearing loss and also to advance discovery programs…
Read More
Otonomy and AGTC Collaborate to Develop and Commercialize Gene Therapy for Congenital Hearing Loss
Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that they have entered into a strategic collaboration to co-develop and co-commercialize an AAV-based…
Read More
Demant Estimates Losses Related to Cyber Attack Possibly as High as $95M
As previously reported, the Demant Group, parent company to the Oticon, Sonic and Bernafon hearing aid brands, experienced a critical incident on its internal IT infrastructure on September 3, 2019. The Group’s IT infrastructure was hit by cyber-crime. According to the latest press release update, the company state that it’s “quick response to the issue…
Read More
Oticon, Inc. Names Leanne Blair as Vice President of Marketing
SOMERSET, NEW JERSEY – Oticon, Inc. has announced the appointment of Leanne Blair as Vice President of Marketing. In her new role, Blair will be responsible for Oticon’s overall marketing strategy, overseeing product management, campaign development, advertising and public relations initiatives. Blair joins the Oticon leadership team with more than 20 years of marketing and…
Read More
Non-invasive Nerve Stimulation May Help Provide Relief During Vestibular Migraine Attacks
MINNEAPOLIS, MINNESOTA – A small preliminary study suggests that non-invasive nerve stimulation may hold promise as a treatment for vestibular migraine attacks. A vestibular migraine is a type of migraine that causes vertigo and dizziness with or without headache pain, a condition for which there are currently no approved treatments. The new study was published…
Read More